Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...
PharmiWeb2d
RNA Therapeutics Market Outlook 2034 | Industry Report
Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...
Esphera SynBio's Exosome Tech Featured on Advancements with Ted Danson on the Bloomberg cable and satellite network
Esphera SynBio Inc. will be featured in an upcoming episode of Advancements, a television program hosted by Ted Danson and ...
EnPlusOne Biosciences Raises $10M in Financing
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced that it had raised additional funding to scale and drive continued ...
ILIAS Biologics Publishes Collaborative Study On Exosome-Based Therapeutics For Brain Neuroinflammation
ILIAS Biologics Inc. Laboratory (Image: ILIAS Biologics Inc. ) ILIAS Biologics Inc. technology (Image: ILIAS Biologics Inc. ) Demonstrating the Potential of Innovative Exosome Technology to Mitigate ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...
Medscape13h
Anti-Factor XI Anticoagulants: Breakthrough or Bust?
The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...